A Review of Tofacitinib Drugs & Pros. and Cons. of Pharmaceutica

January 25, 2016  |  By  | 

Category: Medical, Health

One of the most generally reported adverse responses throughout the very first 3 months in regulated medical tests (happening in greater than or equal to 2 % of clients treated with tofacitinib citrate monotherapy or in combo with DMARDs) were upper respiratory tract infections, frustration, diarrhea, and nasopharyngitis (the "common cold"). Manusaktteva is the leading manufacturer of tofacitinib citrate in india.

More from Jenifer Weisz

Page 1 / 3